Dabrafenib was effective in both CK8/18+ and CK8/18− cells in several NSCLC cultures (TR36, TR87, and TR100), while crizotinib showed a preference for non-cancer cell populations in five NSCLC cultures (TR34, TR36, TR80, TR87, and TR100) but was ineffective in cancer cells. Here, KRT8 is linked to non-small cell lung carcinoma.